• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nature's Sunshine Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    11/6/25 4:44:52 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NATR alert in real time by email
    natr-20251106
    0000275053false00002750532025-11-062025-11-06

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): November 6, 2025

     NS-logo-darkgreen.jpg
    NATURE’S SUNSHINE PRODUCTS, INC.
    (Exact name of registrant specified in its charter)
     
    Utah 001-34483 87-0327982
    (State or other jurisdiction of
    incorporation)
     (Commission File Number) (I.R.S. Employer Identification No.)
     2901 West Bluegrass Blvd., Suite 100
    Lehi, Utah 84043
    (Address of principal executive offices and zip code)

    Registrant’s telephone, including area code:  (801) 341-7900

    N/A
    (Former name and former address, if changed since last report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Title of each ClassTrading SymbolName of each exchange on which registered
    Common Stock, no par valueNATRNasdaq Capital Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§203.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
    ☐



    Item 2.02    Results of Operations and Financial Condition.
     
    On November 6, 2025, Nature’s Sunshine Products, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended September 30, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    The information furnished pursuant to this Item 2.02 and the exhibit hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

    The press release furnished herewith makes reference to non-GAAP financial information, which the Company's management believes assists management and investors in evaluating and comparing period-to-period results in a more meaningful and consistent manner. A reconciliation of GAAP to non-GAAP results is provided in the press release.


    Item 9.01    Financial Statements and Exhibits
    Item No. Exhibit
    99.1 
    Press release issued by the Company, dated November 6, 2025.
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)




    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
     NATURE’S SUNSHINE PRODUCTS, INC.
       
    Dated: November 6, 2025By:/s/ Nathan G. Brower
      Nathan G. Brower, Executive Vice President, General Counsel and Corporate Secretary

    Get the next $NATR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NATR

    DatePrice TargetRatingAnalyst
    5/7/2025$19.00Buy
    DA Davidson
    9/13/2024$18.00Buy
    Canaccord Genuity
    3/9/2022$24.00 → $24.50Buy
    DA Davidson
    11/5/2021$22.00 → $24.00Buy
    DA Davidson
    10/15/2021$22.00Buy
    DA Davidson
    More analyst ratings

    $NATR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DA Davidson resumed coverage on Nature's Sunshine with a new price target

    DA Davidson resumed coverage of Nature's Sunshine with a rating of Buy and set a new price target of $19.00

    5/7/25 8:37:48 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Nature's Sunshine with a new price target

    Canaccord Genuity initiated coverage of Nature's Sunshine with a rating of Buy and set a new price target of $18.00

    9/13/24 7:38:59 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DA Davidson reiterated coverage on Natures Sunshine Products with a new price target

    DA Davidson reiterated coverage of Natures Sunshine Products with a rating of Buy and set a new price target of $24.50 from $24.00 previously

    3/9/22 9:23:08 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nature's Sunshine Reports Strong Third Quarter 2025 Results

    Net Sales up 12% to $128.3 Million, GAAP EPS up 30% to $0.30Adjusted EBITDA up 42% to $15.2 MillionRaised Full-Year Outlook LEHI, Utah, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 12% to $128.3 million compared to $114.6 million (up 10% in constant currency).Gross profit margin increased 200 basis points to 73.3% compared to 71.3%.GAAP net income attributable to common shareholders was $5.3 million, o

    11/6/25 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Sets Third Quarter 2025 Conference Call for Thursday, November 6, 2025, at 5:00 p.m. ET

    LEHI, Utah, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, will conduct a conference call on Thursday, November 6, 2025, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the third quarter ended September 30, 2025. The Company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Kenneth Romanzi and CFO Shane Jones will host the conference call, followed by a question and answer period. Date: Thursday, November 6, 2025Time: 5:00 p.m. Eastern time (3:00 p

    10/23/25 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Appoints Kenneth Romanzi as CEO

    Mr. Romanzi Brings Extensive Leadership and Operational Experience at Prominent, Large-Scale Consumer Packaged Goods Companies and Proven Track Record of Driving Growth and Value Creation LEHI, Utah, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that its Board of Directors has appointed Kenneth Romanzi to succeed Terrence Moorehead as Chief Executive Officer. Mr. Romanzi will assume the role and become a member of the Nature's Sunshine Board of Directors on October 29, 2025. Mr. Romanzi is an experienced CEO and operator with

    10/15/25 9:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    SEC Filings

    View All

    SEC Form 10-Q filed by Nature's Sunshine Products Inc.

    10-Q - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    11/6/25 5:11:13 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    11/6/25 4:44:52 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Products Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    10/15/25 3:45:37 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Global Supply Chain Gonzalez Martin A. converted options into 5,795 shares and covered exercise/tax liability with 1,673 shares, increasing direct ownership by 6% to 69,640 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    11/6/25 4:42:37 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, General Counsel Brower Nathan G converted options into 3,243 shares and covered exercise/tax liability with 985 shares, increasing direct ownership by 5% to 50,535 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    11/6/25 4:42:10 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Chief Financial Officer Jones Leslie Shane covered exercise/tax liability with 1,756 shares and converted options into 4,004 shares, increasing direct ownership by 2% to 108,592 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    11/6/25 4:40:38 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Financials

    Live finance-specific insights

    View All

    Nature's Sunshine Reports Strong Third Quarter 2025 Results

    Net Sales up 12% to $128.3 Million, GAAP EPS up 30% to $0.30Adjusted EBITDA up 42% to $15.2 MillionRaised Full-Year Outlook LEHI, Utah, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 12% to $128.3 million compared to $114.6 million (up 10% in constant currency).Gross profit margin increased 200 basis points to 73.3% compared to 71.3%.GAAP net income attributable to common shareholders was $5.3 million, o

    11/6/25 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Sets Third Quarter 2025 Conference Call for Thursday, November 6, 2025, at 5:00 p.m. ET

    LEHI, Utah, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, will conduct a conference call on Thursday, November 6, 2025, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the third quarter ended September 30, 2025. The Company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Kenneth Romanzi and CFO Shane Jones will host the conference call, followed by a question and answer period. Date: Thursday, November 6, 2025Time: 5:00 p.m. Eastern time (3:00 p

    10/23/25 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Reports Second Quarter 2025 Results

    LEHI, Utah, July 31, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 4% to $114.8 million compared to $110.6 million (up 2% in constant currency).GAAP net income attributable to common shareholders was $5.3 million, or $0.28 per diluted common share, compared to $1.3 million, or $0.07 per diluted common share.Adjusted EBITDA was up 8% to $11.3 million compared to $10.4 million. Management Commentary "We deli

    7/31/25 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Leadership Updates

    Live Leadership Updates

    View All

    Nature's Sunshine Appoints Kenneth Romanzi as CEO

    Mr. Romanzi Brings Extensive Leadership and Operational Experience at Prominent, Large-Scale Consumer Packaged Goods Companies and Proven Track Record of Driving Growth and Value Creation LEHI, Utah, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that its Board of Directors has appointed Kenneth Romanzi to succeed Terrence Moorehead as Chief Executive Officer. Mr. Romanzi will assume the role and become a member of the Nature's Sunshine Board of Directors on October 29, 2025. Mr. Romanzi is an experienced CEO and operator with

    10/15/25 9:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Announces Leadership Transition Plan

    Board Initiates CEO Search Process Terrence Moorehead to Step Down as President and CEO, Once Successor Appointed Company Reaffirms Full Year 2025 Outlook LEHI, Utah, June 02, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Terrence Moorehead has notified the Company's Board of Directors (the "Board") of his decision to step down as President and Chief Executive Officer, effective upon the appointment of a successor. At that time, Mr. Moorehead will also resign as a member of the Board of Directors. The Nature's Sunshine Board ha

    6/2/25 9:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Appoints Heidi Wissmiller as Chairman of the Board

    LEHI, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR), a leading natural health and wellness company of high-quality herbal and nutritional products, today announced the appointment of Heidi Wissmiller as Chairman of the Board of Directors, effective April 30, 2025. She succeeds Richard D. Moss, who has retired after serving as a Director since 2018 and Chairman since 2022. Ms. Wissmiller has served on the Board of Nature's Sunshine since 2020. Over the course of her tenure, she has chaired the Governance and Risk Management Committees. As Chief Growth Officer at Rodan + Fields ("R+F"), the leading skincare brand in North America, Ms. Wissmiller led

    5/5/25 8:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    2/12/24 10:37:49 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    1/31/24 11:56:05 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    2/13/23 2:42:04 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care